	US 12,331,119 B2
	Modified Fc fragment, antibody comprising same, and application thereof
Jing Zhang, Wuhan (CN); Lijuan Fang, Wuhan (CN); Yongxiang Yan, Wuhan (CN); Liang Zeng, Wuhan (CN); and Pengfei Zhou, Wuhan (CN)
Assigned to Wuhan YZY Biopharma Co., Ltd., Wuhan (CN)
Appl. No. 17/432,705
Filed by Wuhan YZY Biopharma Co., Ltd., Wuhan (CN)
PCT Filed Feb. 22, 2019, PCT No. PCT/CN2019/075881 § 371(c)(1), (2) Date Aug. 20, 2021, PCT Pub. No. WO2020/168554, PCT Pub. Date Aug. 27, 2020.
Prior Publication US 2022/0098307 A1, Mar. 31, 2022
Int. Cl. C07K 16/28 (2006.01); C07K 16/30 (2006.01)

CPC C07K 16/2827 (2013.01) [C07K 16/28 (2013.01); C07K 16/2809 (2013.01); C07K 16/2878 (2013.01); C07K 16/2896 (2013.01); C07K 16/3007 (2013.01); C07K 2317/31 (2013.01); C07K 2317/522 (2013.01); C07K 2317/524 (2013.01); C07K 2317/526 (2013.01); C07K 2317/53 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/92 (2013.01); C07K 2319/30 (2013.01)]

8 Claims

1. A polypeptide comprising a modified Fc fragment comprising a human IgG1 CH3 and a human IgG2 CH2 which further comprises a D270A mutation, according to EU numbering, wherein the human IgG2 CH2 comprises an amino acid sequence selected from the group consisting of SEQ ID NO:100, 101, 124, 125, 126 and 127.